Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Jotbody is a specialized biotechnology company focused on the discovery and development of single-domain antibodies, also known as nanobodies or VHH antibodies. Utilizing a proprietary platform, the company generates high-quality nanobodies from camelids and sharks through immunization and phage display technology. Jotbody offers a comprehensive suite of services, including custom library construction, high-throughput screening, and recombinant antibody production for therapeutic and diagnostic applications. Their nanobody solutions are designed to address challenging targets that are often inaccessible to conventional antibodies due to their small size and superior stability. Based in the Hong Kong Science Park, the company serves a global clientele across the pharmaceutical and academic sectors. Jotbody's expertise enables the rapid development of next-generation biologics for oncology, immunology, and infectious diseases.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Jotbody.